November 1, 2018 / 9:09 PM / 10 months ago

FDA panel votes against Alkermes' depression treatment

Nov 1 (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc's experimental depression treatment.

The panel voted 21-2 against the add-on treatment that was aiming to treat major depressive disorder in patients with an inadequate response to standard antidepressant therapies.

The decision comes two days after FDA staff reviewers flagged risks of abuse potential of Alkermes' opioid-based treatment and raised questions on its efficacy. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below